Literature DB >> 12113074

Role of chemotherapy in the management of ovarian cancer.

Maurie Markman1.   

Abstract

Ovarian cancer is a highly chemotherapy-sensitive malignancy. With current treatment, most women presenting with advanced disease will achieve an objective response and experience major and sustained improvement of cancer-related symptoms. Unfortunately, the majority of patients will ultimately recur, such that second-line treatment options will need to be considered. Further complicating the decision-making process in choosing an 'optimal' second-line regimen is a serious paucity of randomized trials in this clinical setting.

Entities:  

Mesh:

Year:  2002        PMID: 12113074     DOI: 10.1586/14737140.2.1.90

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  1 in total

1.  A phase II trial of capecitabine (Xeloda) in recurrent ovarian cancer.

Authors:  P A Vasey; L McMahon; J Paul; N Reed; S B Kaye
Journal:  Br J Cancer       Date:  2003-11-17       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.